A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants in Taiwan.

Trial Profile

A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants in Taiwan.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; Hepatitis B vaccine; Hib-DTaP-poliovirus vaccine; MMR-varicella zoster virus vaccine; Pneumococcal vaccine
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Measles; Meningococcal group B infections; Mumps; Pertussis; Pneumococcal infections; Poliomyelitis; Rubella; Tetanus; Varicella zoster virus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 09 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 30 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top